BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS
11 févr. 2020 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Feb. 11, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc., (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that...
Esperite N.V.: Samples and Database are safe. The recent articles published about CryoSave on loss of samples are poorly informed and defamatory.
10 févr. 2020 01h17 HE
|
Esperite N.V.
Samples and Database are safe Amsterdam, The Netherlands – 10 February 2020 Esperite N.V. (Euronext: ESP, “Esperite”) has noticed several articles in the news, online channels and information blogs...
UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
14 janv. 2020 08h05 HE
|
Cynata Therapeutics Limited
MELBOURNE, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has...
REGENERATIVE MEDICINE FOUNDATION’S BOARD OF DIRECTORS EMBRACES NEW MEMBERS AND VISIONARY LEADERSHIP
03 janv. 2020 09h08 HE
|
Regenerative Medicine Foundation
Washington, DC - (January 2, 2020), Jan. 03, 2020 (GLOBE NEWSWIRE) -- The Regenerative Medicine Foundation (RMF), a not-for-profit organization dedicated tothe advancement of ethical research and...
BrainStorm Selected as Buzz of BIO 2020 Winner
11 déc. 2019 05h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in the development of innovative autologous cellular therapies for highly debilitating...
BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site
25 nov. 2019 06h00 HE
|
BrainStorm Cell Therapeutics Inc.
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology
20 nov. 2019 07h00 HE
|
BrainStorm Cell Therapeutics Inc.
A single transplantation of MSC-NTF cells (NurOwn®) in ALS clinical trial participants met the primary safety endpoint and demonstrated promising stabilization of ALS disease progression of up to...
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
21 oct. 2019 08h30 HE
|
Hemostemix Inc.
CALGARY, Alberta, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF), a biotechnology company developing and commercializing...
Cynata Advances Toward Phase 2 Clinical Trial of Cymerus(TM) MSCs in Patients with Osteoarthritis
04 oct. 2019 08h05 HE
|
Cynata Therapeutics Limited
MELBOURNE, Australia, Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to provide an...
Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity.
01 oct. 2019 04h33 HE
|
Esperite N.V.
Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. Amsterdam, The Netherlands – 1st October 2019 Esperite N.V. (the Group) confirmed on 22nd February...